Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C18H24NO2S.CH3O4S |
| Molecular Weight | 429.551 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COS([O-])(=O)=O.C[N+]3(CCC(O)(C1=CC=CS1)C2=CC=CC=C2)CCOCC3
InChI
InChIKey=JPOKDEDHVLJMIJ-UHFFFAOYSA-M
InChI=1S/C18H24NO2S.CH4O4S/c1-19(11-13-21-14-12-19)10-9-18(20,17-8-5-15-22-17)16-6-3-2-4-7-16;1-5-6(2,3)4/h2-8,15,20H,9-14H2,1H3;1H3,(H,2,3,4)/q+1;/p-1
| Molecular Formula | C18H24NO2S |
| Molecular Weight | 318.454 |
| Charge | 1 |
| Count |
|
| Stereochemistry | MIXED |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 2 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
| Molecular Formula | CH3O4S |
| Molecular Weight | 111.097 |
| Charge | -1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Tiemonium (often used in a form of iodide or methylsulphate salt) is a muscarinic acetylcholine receptor antagonist, which is available in Asia (mainly Bangladesh) for the alleviation of muscle spasms of the intestine, biliary system, uterus and urinary bladder in gastrointestinal, biliary, urinary and gynecological diseases.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2094109 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Palliative | NORVIS Approved UseNorvis is an antispasmodic drug. It reduces muscle spasms of the intestine, biliary system, uterus and urinary bladder. It is indicated for the pain in gastrointestinal and biliary disease in the urology and gynecology such as gastroenteritis, diarrhea, dysentery, biliary colic, enterocolitis, cholecystytis, colonopathyes, mild cystitis, and spasmodic dysmenorrhoea. |
|||
| Palliative | NORVIS Approved UseNorvis is an antispasmodic drug. It reduces muscle spasms of the intestine, biliary system, uterus and urinary bladder. It is indicated for the pain in gastrointestinal and biliary disease in the urology and gynecology such as gastroenteritis, diarrhea, dysentery, biliary colic, enterocolitis, cholecystytis, colonopathyes, mild cystitis, and spasmodic dysmenorrhoea. |
|||
| Palliative | NORVIS Approved UseNorvis is an antispasmodic drug. It reduces muscle spasms of the intestine, biliary system, uterus and urinary bladder. It is indicated for the pain in gastrointestinal and biliary disease in the urology and gynecology such as gastroenteritis, diarrhea, dysentery, biliary colic, enterocolitis, cholecystytis, colonopathyes, mild cystitis, and spasmodic dysmenorrhoea. |
|||
| Palliative | NORVIS Approved UseNorvis is an antispasmodic drug. It reduces muscle spasms of the intestine, biliary system, uterus and urinary bladder. It is indicated for the pain in gastrointestinal and biliary disease in the urology and gynecology such as gastroenteritis, diarrhea, dysentery, biliary colic, enterocolitis, cholecystytis, colonopathyes, mild cystitis, and spasmodic dysmenorrhoea. |
|||
| Palliative | NORVIS Approved UseNorvis is an antispasmodic drug. It reduces muscle spasms of the intestine, biliary system, uterus and urinary bladder. It is indicated for the pain in gastrointestinal and biliary disease in the urology and gynecology such as gastroenteritis, diarrhea, dysentery, biliary colic, enterocolitis, cholecystytis, colonopathyes, mild cystitis, and spasmodic dysmenorrhoea. |
|||
| Palliative | NORVIS Approved UseNorvis is an antispasmodic drug. It reduces muscle spasms of the intestine, biliary system, uterus and urinary bladder. It is indicated for the pain in gastrointestinal and biliary disease in the urology and gynecology such as gastroenteritis, diarrhea, dysentery, biliary colic, enterocolitis, cholecystytis, colonopathyes, mild cystitis, and spasmodic dysmenorrhoea. |
|||
| Palliative | NORVIS Approved UseNorvis is an antispasmodic drug. It reduces muscle spasms of the intestine, biliary system, uterus and urinary bladder. It is indicated for the pain in gastrointestinal and biliary disease in the urology and gynecology such as gastroenteritis, diarrhea, dysentery, biliary colic, enterocolitis, cholecystytis, colonopathyes, mild cystitis, and spasmodic dysmenorrhoea. |
|||
| Palliative | NORVIS Approved UseNorvis is an antispasmodic drug. It reduces muscle spasms of the intestine, biliary system, uterus and urinary bladder. It is indicated for the pain in gastrointestinal and biliary disease in the urology and gynecology such as gastroenteritis, diarrhea, dysentery, biliary colic, enterocolitis, cholecystytis, colonopathyes, mild cystitis, and spasmodic dysmenorrhoea. |
|||
| Palliative | NORVIS Approved UseNorvis is an antispasmodic drug. It reduces muscle spasms of the intestine, biliary system, uterus and urinary bladder. It is indicated for the pain in gastrointestinal and biliary disease in the urology and gynecology such as gastroenteritis, diarrhea, dysentery, biliary colic, enterocolitis, cholecystytis, colonopathyes, mild cystitis, and spasmodic dysmenorrhoea. |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method. | 2010-12 |
|
| 6,7-Difluoro-1,4-dihydro-1-methyl-4-oxo-3-quinolinecarboxylic acid, a newly designed fluorescence enhancement-type derivatizing reagent for amino compounds. | 2010-03 |
|
| Direct asymmetric catalytic thienylaluminum addition to ketones: a concise approach to the synthesis of (S)-tiemonium iodide. | 2009-08-06 |
|
| Orofacial dyskinesia associated with tiemonium. | 2007-12 |
Patents
Sample Use Guides
Recommended oral dose of tiemonium (in form of methylsulphate salt) tablet is 2-6 tablets (100-300 mg) daily in divided dosage as required. Tiemonium can be also given as an injection (5 or 10 mg) three times daily, through Intravenous route or Intramuscular route. Suppository: recommended dose is 1 suppository (each suppository contains 20 mg methylsulphate salt) two or three times daily, through rectal route.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25343691
Human colon cancer cell lines, LOVO, were incubated in 2 ml of fresh complete medium containing 10(-2) M tiemonium methylsulfate for five days. Under the tested concentration tiemonium methylsulfate lead to a decrease of cell proliferation.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 20:51:44 GMT 2025
by
admin
on
Mon Mar 31 20:51:44 GMT 2025
|
| Record UNII |
8PYN0UZM30
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
6504-57-0
Created by
admin on Mon Mar 31 20:51:44 GMT 2025 , Edited by admin on Mon Mar 31 20:51:44 GMT 2025
|
PRIMARY | |||
|
229-386-0
Created by
admin on Mon Mar 31 20:51:44 GMT 2025 , Edited by admin on Mon Mar 31 20:51:44 GMT 2025
|
PRIMARY | |||
|
151420
Created by
admin on Mon Mar 31 20:51:44 GMT 2025 , Edited by admin on Mon Mar 31 20:51:44 GMT 2025
|
PRIMARY | |||
|
SUB15571MIG
Created by
admin on Mon Mar 31 20:51:44 GMT 2025 , Edited by admin on Mon Mar 31 20:51:44 GMT 2025
|
PRIMARY | |||
|
38265
Created by
admin on Mon Mar 31 20:51:44 GMT 2025 , Edited by admin on Mon Mar 31 20:51:44 GMT 2025
|
PRIMARY | RxNorm | ||
|
DTXSID40983580
Created by
admin on Mon Mar 31 20:51:44 GMT 2025 , Edited by admin on Mon Mar 31 20:51:44 GMT 2025
|
PRIMARY | |||
|
8PYN0UZM30
Created by
admin on Mon Mar 31 20:51:44 GMT 2025 , Edited by admin on Mon Mar 31 20:51:44 GMT 2025
|
PRIMARY | |||
|
100000085028
Created by
admin on Mon Mar 31 20:51:44 GMT 2025 , Edited by admin on Mon Mar 31 20:51:44 GMT 2025
|
PRIMARY | |||
|
C020526
Created by
admin on Mon Mar 31 20:51:44 GMT 2025 , Edited by admin on Mon Mar 31 20:51:44 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |